Skip to content

Efficacy and Safety of ATEon reducing body weight and body fat of overweight subjects; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Efficacy and Safety of ATEon reducing body weight and body fat of overweight subjects; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002238
Enrollment
100
Registered
2017-02-22
Start date
2017-01-11
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Consumption of placebo or combined extract of Adenophora triphylla var. japonica Hara , twice a day for 12 weeks ( 750mg/day)

Sponsors

Dong Il Pharmtec
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Subject who voluntarily agree to participate and signs informed consent form 2) 20 years= Age = 60years) 3) 25kg/m^2= BMI =29.9kg/m^2

Exclusion criteria

Exclusion criteria: 1) Subjects with severe cerebrovascular disease, cardiac disease (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator) within recent 6 months 2) Subjects for uncontrolled hypertension(systolicBP = 160 mmHg or diastolicBP = 100 mmHg) 3) Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose = 126 mg/dL or random blood glucose = 200 mg/dL 4) Subjects with TSH(thyroid-stimulating hormone) = 0.1 uIU/ml or = 15 uIU/ml 5) Subjects with Creatinine = 2 times the upper limit of normal 6) Subjects with AST or ALP = 3 times the upper limit of normal 7) Subjects with complaint of severe gastrointestinal symptoms such as heartburn, dyspepsia 8) Subjects who take the medicine that can affect the state of weight change (uptake inhibitors, appetite suppressant, health functional food for diet, antidepressants, ß- blocker, diuretics, contraceptives, steroid, and female sex hormone) within recent 1 months 9) Participation in commercial diet program within the 3 months prior to screening 10) Participation in any clinical trial within the 1 month prior to screening or have a plan to participate in other clinical trial 11) Subjects who get hospitalization, medications or rehabilitation treatments for Alcohol disorders, cardiovascular disease, disorder of central nervous system 12) Subjects with the musculoskeletal disorders or restricted physical activity 13) Women who are pregnant of lactating or planning to pregnant 14) Subjects which in the opinion investigator could affect preclude evaluation of response

Design outcomes

Primary

MeasureTime frame
Chainge in fat percentage(by Dual Energy X-Ray Absorptiometry, DEXA)

Secondary

MeasureTime frame
Brachial circumference, Femoral circumference, Waist circumference, Hip circumference, Waist-hip ratio(WHR);Body mass index(BMI) ;Fat mass, Fat Free Mass(by Dual Energy X-Ray Absorptiometry, DEXA);Mesenteric fat area, Subcutaneous fat area, Total abdominal fat area, Mesenteric fat area/Subcutaneous fat area(by CT);Basal metabolism rate;Blood Lipid ;hs-CRP, Adiponectin, Leptin;Body weight

Countries

Korea, Republic of

Contacts

Public ContactJUNG SOOK

The Catholic University of Korea, Seoul St. Mary's Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026